Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 600,000 shares at $18.03 ($10.5M) on 2025-03-03, disclosed to the SEC on 2025-03-05.
Scheduled sale ($10.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.03 | 166,667 | $3.0M | 28.5% |
| 2 | $18.03 | 166,667 | $3.0M | 28.5% |
| 3 | $17.02 | 133,333 | $2.3M | 21.5% |
| 4 | $17.02 | 133,333 | $2.3M | 21.5% |
| Total | $17.58 avg | 600,000 | $10.5M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |